亚洲精品美女久久久久,亚洲精品久久久久,亚洲精品一区二

中文站

Careers | Investors | Patients and HCPS | Contact us

Careers Investors Patients and HCPS Contact us

Search

# Popular search #

Diabetes Oncology Medical Devices

Company News

Company News Exhibitions Activities

All news 2025 2024 2023 2022 2021 2018

Gan & Lee CEO Du Kai and Brazilian Health Minister?Convene to Forge New Frontiers in Diabetes Prevention and Treatmen
Gan & Lee 2025-04-16
Gan & Lee Pharmaceuticals' Insulin Glargine Receives DRAP Approval in Pakistan
Gan & Lee 2025-04-07
Gan & Lee Pharmaceuticals' Insulin Aspart 30 Receives NPRA Approval in Malaysia
Gan & Lee 2025-03-25
Gan & Lee Pharmaceuticals Announced First Participant Dosed in a Phase 3 Clinical Study (OPTIMUM-1) of Bofanglutide (GZR18) Injection in Chinese Patients with Type 2 Diabetes Mellitus
Gan & Lee 2025-03-19
Gan & Lee Pharmaceuticals Announced First Participant Dosed in a Phase 3 Clinical Study (SUPER-3) of Once-weekly Basal Insulin GZR4 Injection in Chinese Patients with Type 2 Diabetes Mellitus
Gan & Lee 2025-03-19
Gan & Lee Pharmaceuticals Announced First Participant Dosed in a Phase 3 Clinical Study (SUPER-2) of Once-weekly Basal Insulin GZR4 injection in Chinese Patients with type 2 diabetes Mellitus
Gan & Lee 2025-03-19

Our websites

Gangan Technology

You are now leaving the Gan & Lee website.

The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.

Continue Back

Search

Subscribe